Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Paclitaxel With Imatinib Mesylate (Gleevec) in Taxane-pretreated Ovarian and Other Cancers of Mullerian Origin

NCT00840450 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT00840450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00840450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Paclitaxel With Imatinib Mesylate (Gleevec) in Taxane-pretreated Ovarian and Other Cancers of Mullerian Origin
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2007
Completion date
October 31, 2012
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer